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Synaptopodin expression in idiopathic nephrotic syndrome
of childhood
TARAK SRIVASTAVA, ROBERT E. GAROLA, JOAN M. WHITING, and URI S. ALON
Section of Nephrology and Department of Pathology, The Children’s Mercy Hospital, University of Missouri at Kansas City,
Kansas City, Missouri, USA

Synaptopodin expression in idiopathic nephrotic syndrome of
childhood.
Background. Synaptopodin is a proline-rich protein intimately associated with actin microfilaments present in the podocytes’ foot processes. We investigated for synaptopodin expression in children with idiopathic nephrotic syndrome (INS),
including minimal change disease (MCD), diffuse mesangial
hypercellularity (DMH), and focal segmental glomerulosclerosis (FSGS); in children with congenital nephrotic syndrome
of the Finnish type (CNF); and in normal kidney tissue. In
particular, we examined whether an association exists between
synaptopodin expression in podocyte cells and the response
to steroids in INS, and whether synaptopodin expression can
predict FSGS upon the initial kidney biopsy in children who
progress from MCD or DMH to FSGS.
Methods. Immunohistochemistry was performed for synaptopodin expression on renal tissues from MCD (N ⫽ 18), DMH
(N ⫽ 7), FSGS (N ⫽ 13), CNF (N ⫽ 9), and normal children
(N ⫽ 7). Synaptopodin expression in nonsclerosed glomeruli
was quantitated by computerized image analysis on the Optimas娃 software for both luminance (L) and percentage of glomerular area (A).
Results. Synaptopodin expression was absent in areas of
sclerosis. In nonsclerosed glomeruli, synaptopodin was significantly less expressed in all groups of INS and in CNF compared
with normal (P ⬍ 0.0001 for both L and A, in each MCD,
DMH, FSGS, and CNF). In INS, synaptopodin expression decreased in order from MCD to DMH to FSGS, reaching statistical significance between MCD and FSGS (P ⫽ 0.001 for L and
P ⫽ 0.05 for A). Greater synaptopodin expression in podocytes
was associated with a significantly better response to steroid
therapy (P ⬍ 0.05 for both L and A). On the other hand,
the expression of synaptopodin did not predict progression of
MCD or DMH to FSGS.
Conclusion. We conclude that measurement of synaptopodin has the potential to be used as a marker to study the
alteration in podocyte cell and response to therapy in INS.

The visceral glomerular epithelial cell or podocyte is
a terminally differentiated cell in the glomerulus that
plays an important role in glomerular ultrafiltration. Podocytes stabilize the glomerular capillaries, participate in
the barrier function, modulate the ultrafiltration coefficient Kf, and model the glomerular basement membrane
[1]. Podocytes have three structurally and functionally
different segments: the cell body, major processes, and
foot processes [1]. Microtubules in the major processes
are connected to an actin-based contractile microfilament apparatus in the foot process that allows the podocytes to maintain and alter cell shape and perform slow
and directed movements of the foot processes [1, 2]. The
foot processes and slit diaphragms of the podocyte form
a barrier, which allows only certain molecules to filter
into the urine, depending on their size, charge, and shape.
Synaptopodin is a linear, proline-rich protein, intimately
associated with the actin microfilament, and it is expressed exclusively in the foot process of podocytes in
the kidney and in the dendritic spines of the telencephalic
synapses [3]. Synaptopodin is believed to modulate the
actin-based shape and motility of the podocyte foot processes [3]. It is present in only the completely differentiated podocyte, and its expression begins in the capillary
loop stage of glomerular development, at which time the
formation of foot processes also commences [4, 5]. While
synaptopodin is expressed in the foot processes, Wilm’s
tumor-1 (WT-1) protein is exclusively expressed in the
nucleus of the podocyte [6].
On biopsy, the common histologies of idiopathic nephrotic syndrome of childhood (INS) include minimal
change disease (MCD), diffuse mesangial hypercellularity (DMH), and focal segmental glomerulosclerosis (FSGS)
[7]. Idiopathic nephrotic syndrome of childhood is characterized by effacement of foot processes, apical displacement of slit diaphragms, and detachment of podocytes from the glomerular basement membrane that are
then replaced by broad-based cytoplasmic sheets [8–10].
Loss and disaggregation of the actin cytoskeleton precede these ultrastructural changes and onset of protein-
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uria [11, 12]. MCD is characterized by minimal changes
in the glomerulus. It responds well to steroid treatment
and rarely progresses to renal failure. On other hand,
FSGS is characterized by segmental glomerular hyalinosis and sclerosis; it responds poorly to steroid treatment
and frequently progresses to renal failure [13]. The clinical course of DMH lies between MCD and FSGS. MCD
and DMH have been observed to progress to FSGS on
subsequent kidney biopsies, suggesting that these lesions
lie on a continuum [14–17]. The initial therapy to all
forms of INS is by steroids, to which the response can
be diverse, and certain children may need additional immunosuppressive therapy to which they may or may not
respond.
Congenital nephrotic syndrome of the Finnish type
(CNF) occurs from a genetic mutation in the nephrin
protein, normally present in the slit diaphragm of the
foot processes [18, 19]. The disease is characterized by
massive proteinuria starting very early in life, at times
in utero [19, 20]. It does not respond to steroids and needs
aggressive treatment, including continuous albumin infusions, bilateral nephrectomy, and renal replacement therapy in infancy [20].
A decrease or loss of synaptopodin expression was
previously observed in idiopathic FSGS, collapsing FSGS,
and HIV-associated nephropathy [21–23]. On the other
hand, the expression was normal in MCD, mesangioproliferative glomerulonephritis, membranous nephropathy,
and IgA nephropathy [21–23]. Barisoni et al concluded
that in collapsing FSGS, there is a dysregulation of the
podocyte phenotype, which is characterized by lack of
synaptopodin expression [21]. Based on these findings,
we investigated for synaptopodin expression in INS,
CNF, and normal children to examine whether it could
be a key for differentiating among the various entities of
INS. We also looked for a possible association between
synaptopodin expression in INS and response to steroids
and whether synaptopodin expression could predict
FSGS on the initial biopsy in children who progress from
MCD or DMH to FSGS.
METHODS
Kidney biopsies from children with INS were included
in the study only if (1) the histology was consistent with
MCD, DMH, or FSGS as described by the International
Study of Kidney Disease in Children [24]; (2) patients
had a minimum of two years of follow-up from the primary diagnosis of INS to ascertain the response to steroid
therapy; and (3) the tissue in the paraffin block had at
least five nonsclerosed glomeruli. Control tissue (normal) from nephrectomy specimens from children with
Wilm’s tumor and kidney tissue from children with CNF
were included in the study as well. In all, 54 kidney
biopsies were investigated: MCD 18, DMH 7, FSGS 13,
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CNF 9, and normal 7. The age at the time of biopsy was
noted. Children with INS were divided into two groups
based on clinical response to steroid therapy. The standard definition for response to steroid in INS was used
[14]. Children in group A (N ⫽ 19) went into remission
with steroid therapy with/without an eight-week course
of cyclophosphamide. Eleven children had received steroids only, while eight had received in addition an eightweek course of cyclophosphamide. Children in group B
(N ⫽ 19) were either steroid resistant (N ⫽ 12) or steroid
dependent (N ⫽ 7) needing additional immunosuppressive therapy in different combinations, such as cyclophosphamide (N ⫽ 5), chlorambucil (N ⫽ 5), cyclosporine
(N ⫽ 12), azathioprine (N ⫽ 1), or FK 506 (N ⫽ 1). No
further subgrouping was done, as the lack of adequate
numbers in various subgroups made statistical analysis
superfluous. An additional four children who had progressed from MCD or DMH to FSGS were analyzed
separately.
Serial 3 m sections were obtained from the cases
listed previously in this article and were air dried and
heat fixed on slides. The sections were deparaffinized with
xylene and iodine and were rehydrated in graded series
of alcohol. The sections were treated with Target Retrieval Solution (Dako #S1700; Dako Corp., Carpinteria,
CA, USA) in a steamer at 90 to 95⬚C for 20 minutes and
then cooled for 15 minutes. The endogenous avidin and
biotin activity was blocked by egg white and skimmed
milk as described by Miller et al [25]. The sections were
stained by immunohistochemistry on the automated
Dako Autostainer 3400 using Dako’s LSAB ⫹ immunoperoxidase kit with streptavidin conjugated to horseradish peroxidase. Anti-synaptopodin, a mouse monoclonal
antibody (ARP Inc., Belmont, MA, USA) was used in 1:1
dilution for synaptopodin staining. Anti-human WT-1, a
mouse monoclonal antibody (Dako Corp.), was used in
1:100 dilution for WT-1 staining. The staining for WT-1
was performed for tissue quality control for fixation and
processing of the archived tissue. Both positive and negative controls for synaptopodin and WT-1 were run with
each run on the Dako Autostainer 3400. Diaminobenzidine was used as the chromogen.
Kidney biopsies stained by immunohistochemistry for
WT-1 and synaptopodin were first examined by light
microscopy. On light microscopy, WT-1 expression was
scored from 0 to 2⫹. The characteristics of synaptopodin
expression in each group were initially evaluated under
light microscopy and were then further analyzed by computerized image analysis using Optimas娃 software. Optimas娃 is a standard image analysis program used for
quantitative immunohistochemistry [26–28]. Synaptopodin stands out as a distinct brown stain against the
light background of the remaining glomerulus. In each
biopsy, the five maximally stained nonsclerosed glomeruli were analyzed for both luminance and percentage
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Fig. 1. Synaptopodin expression in nonsclerosed glomerulus in (A) normal kidney [area
of staining, 44.6%; luminance gray value (GV),
86.5], (B) minimal change disease (area of staining, 27.6%; luminance GV, 117.5), (C) focal
segmental glomerulosclerosis (area of staining,
1.9%; luminance GV, 160.5), and (D) congenital nephrotic syndrome of the Finnish type
(area of staining, 1.5%; luminance GV, 158.7).
Immunohistochemistry staining using diaminobenzidine as chromogen is shown (⫻400).

glomerular area of synaptopodin staining. Five glomeruli
are considered an adequate sample for diagnosis [29, 30].
In each glomerulus, for luminance, an average gray value
(GV) from 0 to 255 was obtained from 320 data points,
with 0 being equivalent to black and 255 equivalent to
white. The lower the luminance GV, the higher is the
intensity of staining. The percentage glomerular area of
staining was calculated by drawing a region of interest
around the glomerulus and calculating the percentage
of area stained with synaptopodin within the glomerulus
at a fixed color threshold. For each biopsy, the average
for luminance GV and percentage glomerular area from
the five glomeruli was used. To compare luminance GV
and percentage glomerular area among the five groups
of MCD, DMH, FSGS, CNF, and normal children, univariate analysis of variance (ANOVA) was used. Box
plots show the distribution of data in each group: the
minimum, 25th percentile, 50th percentile, 75th percentile, and maximum value. Two-tailed unpaired Student’s
t test was used to compare groups A and B and mean
age among the study groups, and paired t test for analysis
of the group, which progressed to FSGS.
RESULTS
On light microscopy, WT-1 and synaptopodin expression were absent in areas of sclerosis. In nonsclerosed
glomeruli, WT-1 expression was 2⫹ in all normal, MCD,
DMH, FSGS, and CNF tissue specimen. In normal children, the morphology of synaptopodin expression was
intense, linear along the glomerular basement membrane,
thick with very minimal segmental interruption and minimal granulation (that is, granular pattern in staining; Fig.
1A). In MCD, the qualitative expression of synaptopodin

was similar to normals but was weaker in intensity, and
like in normals, it was linear along the glomerular basement membrane; however, at times attenuated in thickness with minimal segmental interruption and minimal
granulation (Fig. 1B). In FSGS, in nonsclerosed glomeruli, synaptopodin expression was very weak with occasional glomeruli showing no expression, and the linear
expression changed to more segmental pattern with
marked interruption (“patchy”) and coarse granulations
(Fig. 1C). In segmentally sclerosed glomerulus, the synaptopodin expression was absent in areas of sclerosis
and was patchy in the rest of the glomerulus. The pattern
for DMH was in between MCD and FSGS. In CNF, the
synaptopodin expression was extremely weak (Fig. 1D).
The results of synaptopodin expression by quantitative
computerized image analysis, for both luminance gray
value and percentage glomerular area of staining in nonsclerosed glomeruli in the five groups, and the mean ⫾
SD for age are shown in Table 1. Children with FSGS
were significantly older, and those with CNF were significantly younger than controls. The distribution of data
of synaptopodin expression in normal, MCD, DMH,
FSGS, and CNF children is shown as box plots for luminance GV in Figure 2A and percentage glomerular area
in Figure 2B. The results of univariate ANOVA of the
data presented in Figure 2 are shown in Tables 2 and 3,
respectively. Synaptopodin was significantly less expressed
in MCD, DMH, FSGS, and CNF children compared
with normal (P ⬍ 0.0001 for both luminance and area).
Among the INS entities, synaptopodin expression decreased in order for both luminance and percentage glomerular area from MCD to DMH to FSGS, reaching
statistical significance between MCD and FSGS (P ⫽
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Table 1. Age of patients and synaptopodin expression on computerized image analysis using Optimas娃 software for luminance on a gray
scale (GV) and percentage glomerular area stained for synaptopodin

Age years
Normal vs. (P value)
Luminance GV
Area percentage

Normal
(N ⫽ 7)

MCD
(N ⫽ 18)

DMH
(N ⫽ 7)

FSGS
(N ⫽ 13)

CNF
(N ⫽ 9)

3.5 ⫾ 1.9
—
78.8 ⫾ 12.2
45.7 ⫾ 6.6

5.2 ⫾ 3.5
0.22
129.9 ⫾ 16.8
15.8 ⫾ 9.6

5.3 ⫾ 3.6
0.26
143.6 ⫾ 23.9
11.4 ⫾ 12.0

9.2 ⫾ 3.8
0.001
155.8 ⫾ 13.4
6.4 ⫾ 6.5

0.8 ⫾ 0.2
0.0008
148.5 ⫾ 4.6
5.6 ⫾ 3.5

The lower the luminance GV, the higher is the intensity of staining. The results are expressed as mean ⫾ SD. Abbreviations are: MCD, minimal change disease;
DMH, diffuse mesangial hypercellularity; FSGS, focal segmental glomerulosclerosis; and CNF, congenital nephrotic syndrome of the Finnish type.

Table 2. Univariate analysis of variance (ANOVA) for normal,
MCD, DMH, FSGS and CNF for luminance GV
based on data presented in Figure 2A
95% Cl of mean difference
Group
Normal
MCD
DMH
FSGS
CNF
MCD
DMH
FSGS
DMH
FSGS

Mean
difference

P

Lower
boundary

Upper
boundary

⫺50.63
⫺66.91
⫺74.74
⫺69.75

⬍0.0001
⬍0.0001
⬍0.0001
⬍0.0001

⫺70.26
⫺90.47
⫺95.42
⫺91.97

⫺30.99
⫺43.34
⫺54.08
⫺47.54

⫺16.27
⫺24.12

0.14
0.001

⫺35.91
⫺40.16

⫹03.36
⫺08.07

⫺07.84

0.81

⫺28.51

⫹12.82

Abbreviations are in Table 1.

Table 3. Univariate analysis of variance (ANOVA) for normal,
MCD, DMH, FSGS and CNF for percent glomerular area based
on data presented in Figure 2B
95% Cl of mean difference
Group
Normal
MCD
DMH
FSGS
CNF
MCD
DMH
FSGS
DMH
FSGS

Mean
difference

P

Lower
boundary

Upper
boundary

29.53
34.99
38.27
40.09

⬍0.0001
⬍0.0001
⬍0.0001
⬍0.0001

18.78
22.09
26.96
27.93

40.28
47.89
49.58
52.26

05.46
08.74

0.61
0.05

⫺5.29
0.04

16.21
17.52

03.28

0.92

⫺8.03

14.59

Abbreviations are in Table 1.

Fig. 2. Box plot distribution of data for synaptopodin expression by
(A) luminance gray value (GV) and (B) percentage of glomerular area
in nonsclerosed glomeruli in normal, minimal change disease (MCD),
diffuse mesangial hypercellularity (DMH), focal segmental glomerulosclerosis (FSGS), and congenital nephrotic syndrome of the Finnish
type (CNF).

0.001 for luminance GV and P ⫽ 0.05 for percentage
glomerular area).
The distribution of data in group A and B is shown
as box plots in Figure 3. The luminance GV for synapto-

podin expression in group A was 132.3 ⫾ 18.8 versus
group B 149.0 ⫾ 18.9 (P ⫽ 0.01), and the percentage
glomerular area for synaptopodin expression in group
A was 15.5% ⫾ 9.0% versus group B, 8.8% ⫾ 10.3%
(P ⫽ 0.039). In group A, the predominant diagnosis was
MCD (N ⫽ 14), and in group B, it was FSGS (N ⫽ 12).
The sensitivity and specificity for synaptopodin expression and good steroid response at luminance GV of ⬍140
and percentage glomerular area of ⬎12% were 68.4 and
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DISCUSSION

Fig. 3. Box plot distribution of data for synaptopodin expression by
(A) luminance gray value (GV) and (B) percentage of glomerular area
in nonsclerosed glomeruli in group A (steroid ⫾ cyclophosphamide
responsive) and group B (steroid resistant or dependent requiring
additional immunosuppressive therapy). Outliers are shown as small
circles.

78.9%, respectively, and the positive predictive value
and negative predictive value were 76.5 and 71.4%, respectively.
In four children with progression from MCD or DMH
to FSGS on successive biopsies, synaptopodin expression
was lower on final biopsy with FSGS (luminance GV,
163.0 ⫾ 17.1; percentage glomerular area, 3.0% ⫾ 4.8%)
compared with initial biopsy (luminance GV, 135.6 ⫾
14.9; percentage glomerular area, 13.4% ⫾ 8.6%); however, because of the small number of subjects, the difference did not reach statistical significance. The results
from the initial biopsy in the four children resembled
the findings in other children with MCD and DMH
rather than FSGS.

Synaptopodin is a linear proline-rich protein that is
intimately associated with actin microfilaments present
in the foot processes of the podocytes. In a puromycin
model of nephrotic syndrome, the actin cytoskeletal
structure is disaggregated with onset of proteinuria and is
completely restored on resolution of proteinuria [11, 12].
One would expect synaptopodin to be altered in INS
because of its association with the actin cytoskeletal apparatus. We did observe a decrease in synaptopodin expression in INS with a decrease in order from MCD to
DMH to FSGS. Barisoni et al reported loss of synaptopodin in collapsing FSGS and HIV nephropathy, but
found no difference between normal and MCD [21].
Kemeny et al observed decrease in synaptopodin even
in early stages of idiopathic FSGS but preserved in MCD
[22]. In both studies, synaptopodin was reported as either
absent or present, but no attempt was made to quantitate
the expression [21, 22]. Indeed, in our study on light
microscopy, the qualitative morphological appearance
of synaptopodin in MCD was almost similar to that of
normal (Fig. 1). However, the expression of synaptopodin was significantly different on quantitative computerized image analysis (Tables 1–3 and Fig. 2). It thus
seems that the loss of synaptopodin expression is not an
“all or none phenomenon,” as suggested in earlier studies, but may vary quantitatively from one entity to another, as well as among children with the same histology
(Figs. 1 and 2). In support of our observation of the
importance of quantitative analysis was the finding of
intermediate expression of synaptopodin in DMH biopsies, which has long been regarded histologically and
clinically as intermediate between MCD and FSGS [17].
Indeed, the synaptopodin expression was between MCD
and FSGS (Table 1). Furthermore, our observation of
much attenuation of synaptopodin expression in FSGS
rather than complete disappearance is supported by the
report by Kihara et al [23]. As in other studies, synaptopodin and WT-1, which are exclusively expressed in podocytes, were absent in areas of sclerosis following replacement of podocytes and other glomerular cells by
hyaline and fibrous tissue [21, 22].
Could the observed difference in synaptopodin expression between INS and normal children be age related
(Table 1)? Although children with FSGS were older,
there was no significant difference between the ages of
children with MCD or DMH and normal children. There
was no correlation between luminance GV or percentage
glomerular area and age of the children (data not shown).
Furthermore, despite the difference in ages between children with FSGS and those with CNF, the expression of
synaptopodin in both groups was very similar (Table 1
and Fig. 2). There was no difference between Caucasian
and African American children (data not shown). Hence,
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it seems unlikely that either age or race played a factor
in the expression of synaptopodin.
Was the observed difference in synaptopodin expression between INS and normal children the result of loss
of podocytes from the glomerulus or possibly an artifact?
The loss of podocytes alone cannot explain the loss of
synaptopodin expression in children with INS, as unlike
children with inflammatory glomerulonephritis, loss of
podocytes in the urine is not observed in children with
MCD [31]. Using double staining technique, Kemeny et
al showed a decrease in synaptopodin expression in FSGS
without loss of podocytes [22]. Synaptopodin and WT-1
are exclusively expressed in podocytes, the former in the
foot processes and the latter in the nucleus. In our study,
the WT-1 expression was abundant in all five categories,
suggesting that the loss of synaptopodin in INS was not
the result of disappearance of podocytes. Therefore, we
do not believe that the observed loss of synaptopodin
expression in INS could have been an artifact.
Minimal change disease and DMH have been shown
to progress to FSGS, and the three entities are believed
to lie along a continuum [14–17]. In most children, MCD
responds well to steroid therapy and has a benign clinical
course, while FSGS responds poorly to steroid therapy
and carries a guarded prognosis for chronic renal failure,
while DMH has a clinical course in between the two.
Thus, on scale of severity, the severity in INS increases
in order from MCD to DMH to FSGS. The treatment
of all three entities starts with corticosteroids. Some children have a good response to steroids or may need an
additional short course of cyclophosphamide to enter
remission. They are also regarded to have a better prognosis (group A). In other children who do not respond to
the previously mentioned protocol, aggressive treatment
with additional immunosuppressive drugs is required.
The prognosis in that group is more guarded (group B).
We found that children in group A had better expression
of synaptopodin than those in group B (Fig. 3). Not
surprisingly, group A was comprised mainly of MCD
and group B of FSGS children. However, in spite of the
statistical significance between groups A and B, the data
could not well predict the steroid responsiveness for the
individual patient. This could partially be explained by
the fact that biopsies of MCD were biased toward more
severe cases of MCD, as children with MCD with immediate response to steroids do not undergo a biopsy. It is
thus possible that the difference between groups A and
B would have been stronger if we had biopsy material
from all children with MCD. The response to immunosuppression treatment in INS lies along a continuum,
and hence, it is difficult to categorize them clearly. The
clinical relevance and statistical strength were lost on
attempts to subgroup the data further, and thus, the
biopsies were grouped empirically into two groups, as
discussed previously in this article. The purpose was to
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evaluate for any association between steroid response
and synaptopodin expression. Unlike adults with INS,
24-hour proteinuria quantitation is not performed on a
routine basis in children with INS, and thus, we did not
have the data on 24-hour proteinuria in all children at
the time of biopsy to estimate a correlation between
proteinuria and synaptopodin expression. There was no
difference between onset of nephrotic syndrome and
timing of renal biopsy between the different groups (data
not shown). Only four children in the described case series
have either elevated creatinine or have progressed to
end-stage renal failure, and therefore, we did not correlate synaptopodin expression and renal outcome as the
sample size was too small to make any statistical analysis.
Children with INS may progress from MCD or DMH
to FSGS. It would be advantageous to have a marker
by which one could predict FSGS as early as the initial
biopsy that still shows findings of MCD or DMH. In four
children who upon their renal biopsies progressed from
MCD or DMH to FSGS, synaptopodin expression failed
to predict FSGS on their initial biopsy, as its expression
on those biopsies was closer to that observed in MCD
rather than FSGS. The sample size was too small to
reach a definite conclusion, and therefore, the predictive
accuracy of this method cannot be ruled out completely
and needs to be investigated further.
As discussed previously in this article, the severity in
INS increases in order from MCD to DMH to FSGS. In
our study, we observed the following: (1) synaptopodin
expression decreased significantly in order from normal
to MCD to DMH to FSGS; (2) synaptopodin expression
decreased significantly in order from normal to group A
to group B; and (3) in children who progressed from
MCD or DMH to FSGS, synaptopodin expression was
lower on final biopsy with FSGS compared with the
initial biopsy. These findings cumulatively suggest that
synaptopodin expression decreases with increasing severity of INS. The disease process in MCD, DMH, and
FSGS is believed to have an immunologic basis, which
has still not been well elucidated. The characteristic
changes of INS are seen in the podocyte cell, and both
albuminuria and FSGS can be produced in vivo by isolated podocyte injury in experimental animals [32, 33].
The decrease in synaptopodin expression in podocytes
indirectly reflects the magnitude of damage suffered by
the podocyte cell with increasing severity in INS.
To test the hypothesis of whether the alteration in
synaptopodin expression is a generalized podocyte cell
phenomenon and not necessarily related to an immunologic injury in INS or to immunosuppressive treatment,
we evaluated synaptopodin expression in CNF, a nonimmune podocyte disease, which is due to mutation in the
nephrin protein and is not treated with immunosuppressive medications [18, 19]. We found synaptopodin expression to be decreased also in CNF. Shih et al have
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recently described a CD2-associated protein (CD2AP)
that anchors nephrin to the actin cytoskeleton in the foot
process in mice [34]. In CD2AP knockout model, the
mice die of renal failure with changes resembling CNF
in the glomerulus [34]. In addition, a decrease in mRNA
for nephrin has been observed in MCD and puromycin
model [35, 36]. We hypothesize that nephrin, CD2AP,
and actin cytoskeletal apparatus are interlinked; changes
in one protein leads to a cascade of changes in associated
proteins in the podocyte foot process leading to loss of
synaptopodin in CNF.
In summary, synaptopodin expression declines with
increasing severity of INS, as suggested by the decrease
in expression from MCD to DMH to FSGS as well as its
lesser expression associated with a worse response to
steroid therapy. Synaptopodin expression could not predict FSGS on the initial biopsy in children who progressed from MCD or DMH to FSGS. The loss of synaptopodin expression is not specific for INS alone but also
is seen in CNF. Thus, it seems that synaptopodin expression is not a part of primary pathophysiological mechanism, but rather is a secondary phenomenon that reflects
the magnitude of damage. We conclude that synaptopodin has a potential to be used as a marker to study
the alteration in podocyte cells and possibly to predict
steroid response in INS, although larger studies are
needed to confirm our observations. Furthermore, our
study indicates that quantitative analysis of synaptopodin expression may yield different results than qualitative-only analysis.
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